JonesResearch initiated coverage of ArriVent Biopharma (AVBP) with a Buy rating and $40 price target ArriVent is the leading oral EGFR TKI in front-line atypical EGFR mutated non-small cell lung cancer – a monotherapy regimen against EGFR exon 20 insertion and PACC mutations, the analyst tells investors in a research note. The firm expects pivotal Phase 3 data from EGFR ex20ins mutated lung cancer in the second half of 2025, and potential FDA approval within 12-15 months.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVBP:
- ArriVent Biopharma price target raised to $40 from $39 at H.C. Wainwright
- ArriVent BioPharma Advances Cancer Pipeline in Q1 2025
- ArriVent BioPharma: Promising Clinical Developments and Strategic Advancements Justify Buy Rating
- ArriVent Biopharma reports Q1 EPS ($1.90), consensus (69c)
- ArriVent Biopharma sees cash, equivalents funding operations into 2H26
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue